Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Cardiff Oncology, Inc. stock logo
CRDF
Cardiff Oncology
$2.45
+0.8%
$3.45
$2.09
$5.64
$161.66M1.543.26 million shs1.01 million shs
Contineum Therapeutics, Inc. stock logo
CTNM
Contineum Therapeutics
$6.95
+3.0%
$4.81
$3.35
$20.55
$174.63M1.04321,783 shs80,516 shs
Grace Therapeutics, Inc. stock logo
GRCE
Grace Therapeutics
$3.28
+2.5%
$3.07
$1.75
$4.97
$44.32M0.7269,867 shs131,997 shs
Lifevantage Corporation stock logo
LFVN
Lifevantage
$14.51
+2.5%
$12.94
$7.09
$27.38
$178.25M0.45109,599 shs90,026 shs
Elon Musk's Next Move Cover

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Cardiff Oncology, Inc. stock logo
CRDF
Cardiff Oncology
+4.29%-5.45%-40.29%-8.99%+7.52%
Contineum Therapeutics, Inc. stock logo
CTNM
Contineum Therapeutics
+4.98%+12.50%+72.19%+75.78%-61.03%
Grace Therapeutics, Inc. stock logo
GRCE
Grace Therapeutics
+3.23%+8.11%-6.98%+18.52%+319,999,900.00%
Lifevantage Corporation stock logo
LFVN
Lifevantage
+2.91%+5.36%+17.90%+12.74%+80.15%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Cardiff Oncology, Inc. stock logo
CRDF
Cardiff Oncology
1.6923 of 5 stars
3.40.00.00.02.21.70.6
Contineum Therapeutics, Inc. stock logo
CTNM
Contineum Therapeutics
2.9592 of 5 stars
3.63.00.00.03.80.80.6
Grace Therapeutics, Inc. stock logo
GRCE
Grace Therapeutics
2.8295 of 5 stars
3.50.00.00.03.50.81.3
Lifevantage Corporation stock logo
LFVN
Lifevantage
4.2423 of 5 stars
3.50.01.72.73.22.51.3
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Cardiff Oncology, Inc. stock logo
CRDF
Cardiff Oncology
2.83
Moderate Buy$10.10312.24% Upside
Contineum Therapeutics, Inc. stock logo
CTNM
Contineum Therapeutics
3.17
Buy$22.50223.74% Upside
Grace Therapeutics, Inc. stock logo
GRCE
Grace Therapeutics
3.00
Buy$12.00265.85% Upside
Lifevantage Corporation stock logo
LFVN
Lifevantage
3.00
Buy$30.50110.20% Upside

Current Analyst Ratings Breakdown

Latest GRCE, CTNM, LFVN, and CRDF Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/6/2025
Cardiff Oncology, Inc. stock logo
CRDF
Cardiff Oncology
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$18.00 ➝ $10.00
7/8/2025
Cardiff Oncology, Inc. stock logo
CRDF
Cardiff Oncology
LADENBURG THALM/SH SH
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$19.00
6/24/2025
Cardiff Oncology, Inc. stock logo
CRDF
Cardiff Oncology
Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageHold$3.50
6/20/2025
Contineum Therapeutics, Inc. stock logo
CTNM
Contineum Therapeutics
William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOutperform
6/18/2025
Cardiff Oncology, Inc. stock logo
CRDF
Cardiff Oncology
William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform
5/19/2025
Contineum Therapeutics, Inc. stock logo
CTNM
Contineum Therapeutics
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$25.00 ➝ $20.00
5/15/2025
Contineum Therapeutics, Inc. stock logo
CTNM
Contineum Therapeutics
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$31.00 ➝ $31.00
(Data available from 8/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Cardiff Oncology, Inc. stock logo
CRDF
Cardiff Oncology
$680K239.70N/AN/A$0.88 per share2.78
Contineum Therapeutics, Inc. stock logo
CTNM
Contineum Therapeutics
$50M3.60N/AN/A$6.62 per share1.05
Grace Therapeutics, Inc. stock logo
GRCE
Grace Therapeutics
N/AN/AN/AN/A$4.86 per shareN/A
Lifevantage Corporation stock logo
LFVN
Lifevantage
$200.16M0.91$0.90 per share16.05$2.05 per share7.08
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Cardiff Oncology, Inc. stock logo
CRDF
Cardiff Oncology
-$45.43M-$0.87N/AN/AN/A-9,344.14%-77.94%-63.65%8/14/2025 (Estimated)
Contineum Therapeutics, Inc. stock logo
CTNM
Contineum Therapeutics
-$42.26M-$2.20N/AN/AN/AN/A-29.75%-28.08%N/A
Grace Therapeutics, Inc. stock logo
GRCE
Grace Therapeutics
-$9.57M-$0.86N/AN/AN/AN/A-20.82%-18.34%N/A
Lifevantage Corporation stock logo
LFVN
Lifevantage
$2.94M$0.6921.03N/A4.12%34.67%15.24%8/27/2025 (Estimated)

Latest GRCE, CTNM, LFVN, and CRDF Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/27/2025Q4 2025
Lifevantage Corporation stock logo
LFVN
Lifevantage
$0.17N/AN/AN/A$57.93 millionN/A
8/14/2025Q2 2025
Cardiff Oncology, Inc. stock logo
CRDF
Cardiff Oncology
-$0.19N/AN/AN/A$0.10 millionN/A
8/12/2025Q1 2026
Grace Therapeutics, Inc. stock logo
GRCE
Grace Therapeutics
-$0.22-$0.21+$0.01-$0.21N/AN/A
8/5/2025Q2 2025
Contineum Therapeutics, Inc. stock logo
CTNM
Contineum Therapeutics
-$0.56-$0.62-$0.06-$0.62$7.50 millionN/A
7/29/2025Q2 2025
Cardiff Oncology, Inc. stock logo
CRDF
Cardiff Oncology
-$0.19-$0.21-$0.02-$0.21$0.11 million$0.12 million
6/20/2025Q4 2025
Grace Therapeutics, Inc. stock logo
GRCE
Grace Therapeutics
-$0.23-$0.21+$0.02$0.01N/AN/A
5/14/2025Q1 2025
Contineum Therapeutics, Inc. stock logo
CTNM
Contineum Therapeutics
-$0.56-$0.62-$0.06-$0.62$7.50 millionN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Cardiff Oncology, Inc. stock logo
CRDF
Cardiff Oncology
N/AN/AN/AN/AN/A
Contineum Therapeutics, Inc. stock logo
CTNM
Contineum Therapeutics
N/AN/AN/AN/AN/A
Grace Therapeutics, Inc. stock logo
GRCE
Grace Therapeutics
N/AN/AN/AN/AN/A
Lifevantage Corporation stock logo
LFVN
Lifevantage
$0.181.24%N/A26.09%3 Years
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Cardiff Oncology, Inc. stock logo
CRDF
Cardiff Oncology
N/A
4.42
4.42
Contineum Therapeutics, Inc. stock logo
CTNM
Contineum Therapeutics
N/A
24.51
24.51
Grace Therapeutics, Inc. stock logo
GRCE
Grace Therapeutics
N/A
11.77
11.77
Lifevantage Corporation stock logo
LFVN
Lifevantage
N/A
1.66
0.98

Institutional Ownership

CompanyInstitutional Ownership
Cardiff Oncology, Inc. stock logo
CRDF
Cardiff Oncology
16.29%
Contineum Therapeutics, Inc. stock logo
CTNM
Contineum Therapeutics
N/A
Grace Therapeutics, Inc. stock logo
GRCE
Grace Therapeutics
6.08%
Lifevantage Corporation stock logo
LFVN
Lifevantage
35.32%

Insider Ownership

CompanyInsider Ownership
Cardiff Oncology, Inc. stock logo
CRDF
Cardiff Oncology
7.70%
Contineum Therapeutics, Inc. stock logo
CTNM
Contineum Therapeutics
11.30%
Grace Therapeutics, Inc. stock logo
GRCE
Grace Therapeutics
11.10%
Lifevantage Corporation stock logo
LFVN
Lifevantage
20.65%
CompanyEmployeesShares OutstandingFree FloatOptionable
Cardiff Oncology, Inc. stock logo
CRDF
Cardiff Oncology
2066.53 million61.40 millionOptionable
Contineum Therapeutics, Inc. stock logo
CTNM
Contineum Therapeutics
3125.87 million22.95 millionN/A
Grace Therapeutics, Inc. stock logo
GRCE
Grace Therapeutics
N/A13.83 million12.29 millionN/A
Lifevantage Corporation stock logo
LFVN
Lifevantage
26012.59 million9.99 millionOptionable

Recent News About These Companies

LifeVantage To Open Iceland Market

New MarketBeat Followers Over Time

Media Sentiment Over Time

Cardiff Oncology stock logo

Cardiff Oncology NASDAQ:CRDF

$2.45 +0.02 (+0.82%)
Closing price 04:00 PM Eastern
Extended Trading
$2.44 -0.01 (-0.20%)
As of 07:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor to treatment a range of solid tumor cancers and KRAS/NRAS-mutated metastatic colorectal and metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab. The company primarily serves pharmaceutical manufacturers. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2012. Cardiff Oncology, Inc. was incorporated in 1999 and is headquartered in San Diego, California.

Contineum Therapeutics stock logo

Contineum Therapeutics NASDAQ:CTNM

$6.95 +0.20 (+2.96%)
Closing price 04:00 PM Eastern
Extended Trading
$6.94 -0.02 (-0.22%)
As of 05:50 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing novel oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need. Its lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and progressive multiple sclerosis (MS). The company also develops PIPE-307, a novel, small molecule selective inhibitor of the muscarinic type 1 M1 receptor to treat depression and relapse remitting MS; and CTX-343, a peripherally-restricted LPA1R antagonist. Contineum Therapeutics, Inc. was formerly known as Pipeline Therapeutics, Inc. and changed its name to Contineum Therapeutics, Inc. in November 2023. The company was incorporated in 2009 and is headquartered in San Diego, California.

Grace Therapeutics stock logo

Grace Therapeutics NASDAQ:GRCE

$3.28 +0.08 (+2.50%)
As of 03:59 PM Eastern

Grace Therapeutics Inc. is a late-stage biopharma company advancing GTx-104, its novel injectable formulation of nimodipine which addresses high unmet medical needs for a rare disease, aneurysmal subarachnoid hemorrhage. Grace Therapeutics Inc., formerly known as Acasti Pharma Inc., is based in Princeton, New Jersey.

Lifevantage stock logo

Lifevantage NASDAQ:LFVN

$14.51 +0.35 (+2.47%)
Closing price 04:00 PM Eastern
Extended Trading
$14.70 +0.19 (+1.31%)
As of 04:46 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

LifeVantage Corporation engages in the identification, research, development, formulation, and sale of advanced nutrigenomic activators, dietary supplements, nootropics, pre- and pro-biotics, weight management, skin and hair care, bath and body, and targeted relief products. It offers Protandim, a dietary supplement; LifeVantage Omega+, a dietary supplement that combines DHA and EPA Omega-3 fatty acids, Omega-7 fatty acids, and vitamin D3; LifeVantage ProBio, a dietary supplement to support gut health; PhysIQ, a weight management system; LifeVantage IC Bright, a supplement to support eye and brain health, reduce eye fatigue and strain, supports cognitive functions, and support normal sleep patterns; Petandim for Dogs, a supplement to combat oxidative stress in dogs; and Axio, a nootropic energy drink mix. The company also provides anti-aging skin care products, including liquid collagen, facial cleansers, perfecting lotions, eye serums, anti-aging creams, hand creams, beauty serum, as well as hair care products, such as invigorating shampoos, nourishing conditioners, and scalp serums under the LifeVantage TrueScience brand name. In addition, it offers bath and body, and targeted relief products, such as body lotion, body wash, body butter, deodorant, soothing balm, and body rub under the TrueScience brand name. It sells its products through its website and network of independent distributors in the United States, Mexico, Japan, Australia, Hong Kong, Canada, Thailand, the United Kingdom, the Netherlands, Germany, Taiwan, Austria, Spain, Ireland, Belgium, New Zealand, Singapore, and the Philippines. The company was founded in 2003 and is headquartered in Lehi, Utah.